Roche: encouraging results in lupus nephritis
(CercleFinance.com) - Roche announces that the detailed analysis of the Phase III REGENCY trial of Gazyva/Gazyvaro (obinutuzumab) for the treatment of active lupus nephritis has been published in the New England Journal of Medicine.
The study shows a statistically significant improvement in the complete renal response (CRR) rate at 76 weeks, reaching 46.4% with Gazyva/Gazyvaro combined with standard therapy, vs. 33.1% with standard therapy alone.
The results were presented at the 2025 World Congress of Nephrology and submitted to health authorities.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The study shows a statistically significant improvement in the complete renal response (CRR) rate at 76 weeks, reaching 46.4% with Gazyva/Gazyvaro combined with standard therapy, vs. 33.1% with standard therapy alone.
The results were presented at the 2025 World Congress of Nephrology and submitted to health authorities.
Copyright (c) 2025 CercleFinance.com. All rights reserved.